The tremendous success of mRNA vaccine during the COVID-19 pandemic has captured attention globally and highlighted the transformative potential of mRNA technology in addressing infectious diseases[1].In comparison to...The tremendous success of mRNA vaccine during the COVID-19 pandemic has captured attention globally and highlighted the transformative potential of mRNA technology in addressing infectious diseases[1].In comparison to conventional protein antibody-based therapies,the delivery of mRNA-encoding antibod-ies presents a cost-effective and versatile approach with several advantages.These include eliminating the laborious process of in vitro protein expression,enabling flexible manufacturing processes,and eliciting rapid therapeutic responses[2-4].However,the clinical application of mRNA-encoded antibodies for infectious diseases remains limited to date,only one such construct-mRNA-1944-has been assessed in non-human primates and approved for phase I clinical trial[5,6].Several challenges hampered the broader clinical application of mRNA-encoded antibody therapies,including the requirement for higher dosages for intravenous administration,limited pharmacodynamic and pharmacokinetics data,as well as the lack of safety and efficacy profiles in non-human primates[7].展开更多
基金supported by the National Key Research and Development Project of China(2022YFC2304100 and 2021YFC2302400)the National Natural Science Foundation of China(82371833,82350801,and 82222041)+1 种基金Cheng-Feng Qin was supported by the National Science Fund for Distinguished Young Scholars(81925025)the Innovation Fund for Medical Sciences(2019-I2M-5-049)from the Chinese Academy of Medical Sciences.
文摘The tremendous success of mRNA vaccine during the COVID-19 pandemic has captured attention globally and highlighted the transformative potential of mRNA technology in addressing infectious diseases[1].In comparison to conventional protein antibody-based therapies,the delivery of mRNA-encoding antibod-ies presents a cost-effective and versatile approach with several advantages.These include eliminating the laborious process of in vitro protein expression,enabling flexible manufacturing processes,and eliciting rapid therapeutic responses[2-4].However,the clinical application of mRNA-encoded antibodies for infectious diseases remains limited to date,only one such construct-mRNA-1944-has been assessed in non-human primates and approved for phase I clinical trial[5,6].Several challenges hampered the broader clinical application of mRNA-encoded antibody therapies,including the requirement for higher dosages for intravenous administration,limited pharmacodynamic and pharmacokinetics data,as well as the lack of safety and efficacy profiles in non-human primates[7].
